)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
ImmuPharma
ImmuPharma (IMM) investor relations material
ImmuPharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary15 Sep, 2026
Executive summary
Reported an operating loss of £1.1 million for H1 2026, slightly improved from £1.2 million in H1 2025.
Overall loss increased to £4.7 million from £1.9 million due to a £3.36 million finance loss on derivative financial asset revaluation.
Raised £6.47 million in equity funding to support accelerated development of Kapiglucagon and maintain P140 as a priority.
Cash runway expected to extend to at least H2 2028 following fundraising.
Continued progress on P140 and Kapiglucagon development, with focus on scientific, regulatory, and commercial milestones.
Financial highlights
Operating loss for H1 2026: £1.1 million (H1 2025: £1.2 million).
R&D expenses: £0.6 million (H1 2025: £0.7 million); administrative expenses: £0.4 million.
Net loss: £4.7 million (H1 2025: £1.9 million), mainly due to derivative financial asset fair value loss.
Cash balance at 30 June 2026: £0.7 million (30 June 2025: £0.4 million).
Derivative financial asset valued at £2 million, up from £0.6 million a year earlier.
Outlook and guidance
Cash runway projected to last until at least H2 2028.
Focus remains on advancing P140 and Kapiglucagon, with a goal to secure a commercial deal for P140 in 2026.
Continued disciplined development expenditure and partnering strategy.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ImmuPharma
- Advanced P140, reduced losses, and strengthened cash position amid ongoing funding risks.IMM
H2 2025 - Accelerated funding supports P140 licensing and Kapiglucagon's rapid Type 1 diabetes development.IMMInvestor update
- Loss increased on higher R&D, but P140 advances and new funding support future growth.IMMH1 2025
- Operating loss reduced, cash position improved, and late-stage clinical pipeline advanced.IMMH1 2024
- P140 clinical programs advanced, fundraising bolstered liquidity, but going concern risks persist.IMMH2 2023
- Losses narrowed and scientific advances achieved, but funding and going concern risks remain.IMMH2 2024
ImmuPharma
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage